| Article Access Statistics | | | Viewed | 19789 | | | Printed | 348 | | | Emailed | 17 | | | PDF Downloaded | 329 | | | Comments | [Add] | | | Cited by others | 12 | | |
|
Click on image for details.
|
|
| LETTER TO EDITOR |
|
|
|
| Year : 2005 | Volume
: 53
| Issue : 3 | Page : 372-373 |
Acute painful peripheral neuropathy due to metronidazole
G RK Sarma, V Kamath
Dept. of Neurology St. John's Medical college hospital, Bangalore 560034, India
| Date of Acceptance | 28-Jun-2005 |
Correspondence Address:
G RK Sarma
Dept. of Neurology St. John's Medical college hospital, Bangalore 560034
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0028-3886.16955
How to cite this article:
Sarma G R, Kamath V. Acute painful peripheral neuropathy due to metronidazole. Neurol India 2005;53:372-3 |
Sir,
Metronidazole is a 5-nitroimidazole compound that has potent activity against anaerobic bacteria and several protozoa. Peripheral neuropathy is its rare side effect.[1] We report an unusually rapid development of peripheral neuropathy due to metronidazole. A 45-year-old lady received oral metronidazole for the treatment of vaginitis. After 3 days of treatment, after receiving 3.6 g of metronidazole, she developed severe burning pain in both the feet and aching pain in the muscles of the thighs and calves. On the seventh day she developed burning pain in the hands and fingers and severe aching pain in the muscles of forearms and arms. There were no history of diabetes mellitus, chronic alcohol intake, renal failure, occupational toxin exposure or chronic diarrhoea. She consumed wholesome non-vegetarian diet. There was no history of arthritis, skin rash, recurrent oral ulcers, uveitis, xerostomia or xeropthalmia.
Examination revealed a well-nourished middle-aged lady. There was no pallor, hyper-pigmentation, and evidence of nutritional deficiencies or hypopigmented skin lesions. She weighed 65 kg and her height was 154 cm. Her blood pressure was 120/ 70 mm Hg. She had no organomegaly. Detailed neurological examination was normal. Her hemogram, peripheral smear, fasting blood sugar, serum creatinine and serum vitamin B12 level were normal. Antinuclear antibodies were negative.
Electrophysiological studies done on the 10th day of illness revealed prolonged distal motor latency (6.5 ms for a distance of 90mm) of posterior tibial nerve, prolonged distal motor latency (5.3 ms for a distance of 90mm) and mildly reduced compound muscle action potential amplitude (3.1mV) of the peroneal nerve and decreased sensory nerve action potential amplitude (2.0 mV) of the posterior tibial nerve. Nerve conduction studies of median, ulnar and sural nerves were normal. Metronidazole was discontinued and symptomatic therapy (Carbamazepine and Gabapentin) was given. She found significant relief of symptoms. After 3 months, she continued to take carbamazepine and gabapentin for symptomatic relief. A repeat nerve conduction study at 3 months did not show any improvement in the abnormalities. Applying the Naranjo's algorithm,[2] our patient's neuropathy could be considered a "probable (score +5)" adverse effect of metronidazole.
The cumulative neurotoxic dose of metronidazole in the literature varied from 13.2 grams[3] to 228 grams.[4] The duration of therapy after which neuropathic symptoms developed varied from 11 days[3] to 6 months.[4] The 3 days of latency and 3.6 g of cumulative dose observed in our patient are the smallest reported so far. It is noteworthy that, in the case reports from India,[3],[5], the cumulative dose of metronidazole was low (13.2-18 grams) and the latency to symptom onset very short (11 days to 18 days) when compared to patients from the West. This may reflect a genetic susceptibility to the neurotoxic effects of metronidazole or a genetic variation in the metabolism of metronidazole in Indian patients.
To conclude, we report an unusually rapid development of peripheral neuropathy after starting metronidazole. Its early recognition and rapid withdrawal of the drug are important, as the neuropathy can be disabling and persistent.
| References | |  |
| 1. | Rustscheff S, Hulten S. An unexpected and severe neurological disorder with permanent disability aquired during short course treatment with metronidazole. Scand J Infect Dis 2003;53:279-80.  |
| 2. | Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45. |
| 3. | Pais P, Balasubramaniam KR Metronidazole-peripheral neuropathy. (Letter to Editor). JAPI 1982;30:918-9. |
| 4. | Bradley WG, Karlson IJ, Rassol CG. Metronidazole neuropathy. Br Med J 1977;2:610-11. |
| 5. | Kapoor K, Chandra M, Nag D, Paliwal JK, Gupta RC, Saxena RC. Evaluation of metronidazole toxicity: a prospective study. Int J Clin Pharmacol Res 1999;19:3:83-8. |
| This article has been cited by | | 1 |
Clinical relevance of metronidazole and peripheral neuropathy: a systematic review of the literature |
|
| Tiffany A. Goolsby,Bernadette Jakeman,Robert P. Gaynes | | International Journal of Antimicrobial Agents. 2017; | | [Pubmed] | [DOI] | | | 2 |
Contracciones involuntarias, rigidez cervical grave y cervicalgia tras la toma de metronidazol |
|
| J. Morera-Montes,M. Stuhec | | SEMERGEN - Medicina de Familia. 2017; 43(3): 249 | | [Pubmed] | [DOI] | | | 3 |
Neurologic Complications of Metronidazole |
|
| Justyna R. Sarna,Sarah Furtado,A. Keith W. Brownell | | The Canadian Journal of Neurological Sciences. 2013; 40(06): 768 | | [Pubmed] | [DOI] | | | 4 |
A Rare Adverse Effect of Metronidazole |
|
| Ihsan Kafadar,Fatma Moustafa,Koray Yaln,Betl Aydn Kl | | Pediatric Emergency Care. 2013; 29(6): 751 | | [Pubmed] | [DOI] | | | 5 |
Neurotoxic effects associated with antibiotic use: management considerations |
|
| Marie F. Grill,Rama K. Maganti | | British Journal of Clinical Pharmacology. 2011; 72(3): 381 | | [Pubmed] | [DOI] | | | 6 |
Painful neuropathy due to skin denervation after metronidazole-induced neurotoxicity |
|
| Tan, C.-H., Chen, Y.-F., Chen, C.-C., Chao, C.-., Liou, H.-H., Hsieh, S.-T. | | Journal of Neurology, Neurosurgery and Psychiatry. 2011; 82(4): 462-465 | | [Pubmed] | | | 7 |
Clinical, neuroimaging and pathological features of 5-nitroimidazole- induced encephalo-neuropathy in two patients: Insights into possible pathogenesis |
|
| Chacko, J. and Pramod, K. and Sinha, S. and Saini, J. and Mahadevan, A. and Bharath, R.D. and Bindu, P.S. and Yasha, T.C. and Taly, A.B. | | Neurology India. 2011; 59(5): 743-747 | | [Pubmed] | | | 8 |
Neurotoxic effects associated with antibiotic use: Management considerations |
|
| Grill, M.F. and Maganti, R.K. | | British Journal of Clinical Pharmacology. 2011; 72(3): 381-393 | | [Pubmed] | | | 9 |
When an antibiotic becomes toxic [Quand lantibiotique devient toxique] |
|
| Batjom, E. and Franck, L. and Dubost, C. and Rouquette-Vincenti, I. | | Annales Francaises dAnesthesie et de Reanimation. 2009; 28(1): 105-106 | | [Pubmed] | | | 10 |
Permanent polyneuropathy dur to metronidazole [Polineuropatía permanente por metronidazol] |
|
| Ma Teresa, M.L. and Nuria, B.R. and Ángel, P.S. and Francisco, M.G. | | Atencion Farmaceutica. 2009; 11(1): 57-59 | | [Pubmed] | | | 11 |
When an antibiotic becomes toxic | [Quand lantibiotique devient toxique] |
|
| Batjom, E., Franck, L., Dubost, C., Rouquette-Vincenti, I. | | Annales Francaises dAnesthesie et de Reanimation. 2009; 28(1): 1-2 | | [Pubmed] | | | 12 |
Permanent polyneuropathy dur to metronidazole | [Polineuropata permanente por metronidazol] |
|
| Ma Teresa, M.L., Nuria, B.R., ngel, P.S., Francisco, M.G. | | Atencion Farmaceutica. 2009; 11(1): 1-2 | | [Pubmed] | |
|
|
|
|
|
|
|
|
